Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries

Infection management for pediatric cancer patients may be compromised in low and middle income countries (LMICs) if key antimicrobials are not included in national essential medicines lists. We screened national essential medicines lists for 81 LMICs, and assessed the frequency and corresponding 95%...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2015-02, Vol.62 (2), p.204-207
Main Authors: Kirby, Jeannette, Ojha, Rohit P., Johnson, Kyle M., Bittner, Elizabeth C., Caniza, Miguela A.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - economics
Anti-Bacterial Agents - therapeutic use
Antifungal Agents - economics
Antifungal Agents - therapeutic use
antimicrobials
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Bacterial Infections - drug therapy
Drugs, Essential - economics
essential medicines
Hematology
Humans
infections
low and middle income countries
Mycoses - drug therapy
Neoplasms - therapy
Oncology
pediatric cancer
Pediatrics
Socioeconomic Factors
Virus Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infection management for pediatric cancer patients may be compromised in low and middle income countries (LMICs) if key antimicrobials are not included in national essential medicines lists. We screened national essential medicines lists for 81 LMICs, and assessed the frequency and corresponding 95% confidence limits (CL) of countries that included the 15 International Society of Paediatric Oncology‐recommended antimicrobial agents. Only 19% (95% CL: 11%, 28%) of countries included all recommended antimicrobials in their national essential medicines lists. The selection of antimicrobial agents for national essential medicines lists in LMICs warrants attention from a pediatric cancer perspective. Pediatr Blood Cancer 2015;62:204–207. © 2014 Wiley Periodicals, Inc.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.25273